EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2
- PMID: 15455380
- DOI: 10.1002/ijc.20612
EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2
Abstract
In advanced prostate cancer, cellular changes occur leading to a transition from androgen-dependent to androgen-independent growth. During this transition, proliferation of androgen-dependent prostate cancer cells becomes more and more dependent on growth factors, like the epidermal growth factor (EGF). Endocytosis of growth factor receptors, one of the mechanisms that controls growth factor signalling, was observed to be markedly changed in advanced metastatic prostate cancer. Internalisation and signalling of EGF receptors was examined in different prostate cancer cell lines, in relation to the expression level of the endocytosis-related REPS2 gene. It was observed that a high level of REPS2 correlates with reduced EGF-internalisation. To investigate this more thoroughly, prostate cancer cells with inducible REPS2 expression were generated. Using these cells, it was found that REPS2-induction indeed results in reduction of EGF-internalisation. Furthermore, when EGF receptor signalling was evaluated, by examination of mRNA expression for several EGF-responsive genes (EGF receptor, EGR-1, Fos and Jun), it was observed that induced expression of REPS2 exerts an inhibiting effect on this signalling. From these experiments, it is concluded that increased REPS2 expression negatively affects EGF receptor internalisation and subsequent signalling. Therefore, decreased REPS2 expression during prostate cancer progression, observed in earlier work, may result in enhanced EGF receptor expression and signalling, which could add to the androgen-independent state of advanced prostate cancer.
Similar articles
-
REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells.Oncogene. 2003 May 15;22(19):2920-5. doi: 10.1038/sj.onc.1206397. Oncogene. 2003. PMID: 12771942
-
Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.Anticancer Res. 2000 Jan-Feb;20(1A):91-5. Anticancer Res. 2000. PMID: 10769639
-
Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling.Endocr Relat Cancer. 2005 Mar;12(1):135-48. doi: 10.1677/erc.1.00897. Endocr Relat Cancer. 2005. PMID: 15788645
-
Growth factor receptors and oncogene expression in prostate cells.Am J Clin Oncol. 1988;11 Suppl 2:S1-7. doi: 10.1097/00000421-198801102-00002. Am J Clin Oncol. 1988. PMID: 2468269 Review.
-
Egr1 signaling in prostate cancer.Cancer Biol Ther. 2003 Nov-Dec;2(6):617-22. Cancer Biol Ther. 2003. PMID: 14688464 Review.
Cited by
-
Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.Prostate. 2016 Oct;76(14):1239-56. doi: 10.1002/pros.23211. Epub 2016 Jun 8. Prostate. 2016. PMID: 27272349 Free PMC article.
-
Identification a novel set of 6 differential expressed genes in prostate cancer that can potentially predict biochemical recurrence after curative surgery.Clin Transl Oncol. 2019 Aug;21(8):1067-1075. doi: 10.1007/s12094-018-02029-z. Epub 2019 Jan 12. Clin Transl Oncol. 2019. PMID: 30637711
-
The central proline rich region of POB1/REPS2 plays a regulatory role in epidermal growth factor receptor endocytosis by binding to 14-3-3 and SH3 domain-containing proteins.BMC Biochem. 2008 Jul 22;9:21. doi: 10.1186/1471-2091-9-21. BMC Biochem. 2008. PMID: 18647389 Free PMC article.
-
Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP-on-chip.Genome Biol. 2008;9(11):R166. doi: 10.1186/gb-2008-9-11-r166. Epub 2008 Nov 25. Genome Biol. 2008. PMID: 19032775 Free PMC article.
-
Endocytic adaptor protein epsin is elevated in prostate cancer and required for cancer progression.ISRN Oncol. 2013 Apr 4;2013:420597. doi: 10.1155/2013/420597. Print 2013. ISRN Oncol. 2013. PMID: 23691361 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous